Terms: = Pancreatic cancer AND SALL4, ENSG00000101115, 57167, Q9UJQ4, ZNF797, MGC133050, HSAL4, DRRS, dJ1112F19_1 AND Treatment
13692 results:
1. Intelligent nanovesicle for remodeling tumor microenvironment and circulating tumor chemoimmunotherapy amplification.
Huai M; Wang Y; Li J; Pan J; Sun F; Zhang F; Zhang Y; Xu L
J Nanobiotechnology; 2024 May; 22(1):257. PubMed ID: 38755645
[TBL] [Abstract] [Full Text] [Related]
2. Impact on Long-term Survival of a Standardized Histopathological Protocol on the R1 Incidence in Pancreatoduodenectomy for pancreatic Ductal Adenocarcinoma.
Moiş E; Graur F; Puia C; Vlad I; Moldovan S; Ursu CP; Nechita VI; Vălean D; Furcea L; Puia A; Zaharie F; Popa C; Bodea R; Iancu C; Rusu I; Hajjar NA
Chirurgia (Bucur); 2024 Apr; 119(2):171-183. PubMed ID: 38743830
[No Abstract] [Full Text] [Related]
3. Multiple asynchronous recurrence as a predictive factor for refractoriness against locoregional and surgical therapy in patients with intermediate-stage hepatocellular carcinoma.
Kasuga R; Taniki N; Chu PS; Tamura M; Tabuchi T; Yamaguchi A; Hayatsu S; Koizumi J; Ojiro K; Hoshi H; Kaneko F; Morikawa R; Noguchi F; Yamataka K; Usui S; Ebinuma H; Itano O; Hasegawa Y; Abe Y; Kitago M; Inoue M; Nakatsuka S; Jinzaki M; Kitagawa Y; Kanai T; Nakamoto N
Sci Rep; 2024 May; 14(1):10896. PubMed ID: 38740983
[TBL] [Abstract] [Full Text] [Related]
4. MKLN1-AS promotes pancreatic cancer progression as a crucial downstream mediator of HIF-1α through miR-185-5p/TEAD1 pathway.
Chen J; Li L; Feng Y; Zhao Y; Sun F; Zhou X; Yiqi D; Li Z; Kong F; Kong X
Cell Biol Toxicol; 2024 May; 40(1):30. PubMed ID: 38740637
[TBL] [Abstract] [Full Text] [Related]
5. Enrichment and Evaluation of Antitumor Properties of Total Flavonoids from
Yang S; Chu G; Wu J; Zhang G; Du L; Lin R
Molecules; 2024 Apr; 29(9):. PubMed ID: 38731467
[TBL] [Abstract] [Full Text] [Related]
6. The influence of delayed gastric emptying on quality of life after partial duodenopancreatectomy.
Klein M; Warschkow R; Ukegjini K; Krstic D; Burri P; Chatziisaak D; Steffen T; Schmied B; Probst P; Tarantino I
Langenbecks Arch Surg; 2024 May; 409(1):155. PubMed ID: 38727871
[TBL] [Abstract] [Full Text] [Related]
7. Exosomal PD-L1 in cancer and other fields: recent advances and perspectives.
Lu MM; Yang Y
Front Immunol; 2024; 15():1395332. PubMed ID: 38726017
[TBL] [Abstract] [Full Text] [Related]
8. Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of pancreatic Carcinomas: In Search of Therapeutic Targets.
Faber EB; Krause HB; Amin K; Walker P; Hosein PJ; Shields AF; Lenz HJ; Prakash A; Goel S; Oberley M; Malleo G; Luchini C; Hwang J; Florou V; Garrido-Laguna I; Lou E
JCO Precis Oncol; 2024 May; 8():e2300595. PubMed ID: 38723231
[TBL] [Abstract] [Full Text] [Related]
9. Immune checkpoint inhibitor associated diarrhoea.
Al-Hussainy A; Adams J; Simmons J; Kennedy J
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38719255
[TBL] [Abstract] [Full Text] [Related]
10. [Analysis of factors affecting the prognosis of patients with pancreatic cancer patients with obstructive jaundice].
Zhang L; Li M; Sun QF; Yu HP
Zhonghua Nei Ke Za Zhi; 2024 May; 63(5):474-479. PubMed ID: 38715484
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.
Zhang P; Chen Z; Shi S; Li Z; Ye F; Song L; Zhang Y; Yin F; Zhang X; Xu J; Cheng Y; Su W; Shi M; Fan S; Tan P; Zhong C; Lu M; Shen L
Cancer Immunol Immunother; 2024 May; 73(7):119. PubMed ID: 38713205
[TBL] [Abstract] [Full Text] [Related]
12. Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study.
Hompland I; Boye K; Wiedswang AM; Papakonstantinou A; Røsok B; Joensuu H; Bruland Ø
Acta Oncol; 2024 May; 63():288-293. PubMed ID: 38712513
[TBL] [Abstract] [Full Text] [Related]
13. treatment strategies for borderline resectable pancreatic neuroendocrine tumors: a narrative review.
Chang JY; Ruff SM; Cloyd JM
Chin Clin Oncol; 2024 Apr; 13(2):25. PubMed ID: 38711178
[TBL] [Abstract] [Full Text] [Related]
14. Significance of
Lin H; Wang J; Shi Q; Wu M
PeerJ; 2024; 12():e17338. PubMed ID: 38708353
[TBL] [Abstract] [Full Text] [Related]
15. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
Burris HA; Okusaka T; Vogel A; Lee MA; Takahashi H; Breder V; Blanc JF; Li J; Bachini M; Żotkiewicz M; Abraham J; Patel N; Wang J; Ali M; Rokutanda N; Cohen G; Oh DY
Lancet Oncol; 2024 May; 25(5):626-635. PubMed ID: 38697156
[TBL] [Abstract] [Full Text] [Related]
16. NRDE2 deficiency impairs homologous recombination repair and sensitizes hepatocellular carcinoma to PARP inhibitors.
Wang Y; Liu X; Zuo X; Wang C; Zhang Z; Zhang H; Zeng T; Chen S; Liu M; Chen H; Song Q; Li Q; Yang C; Le Y; Xing J; Zhang H; An J; Jia W; Kang L; Zhang H; Xie H; Ye J; Wu T; He F; Zhang X; Li Y; Zhou G
Cell Genom; 2024 May; 4(5):100550. PubMed ID: 38697125
[TBL] [Abstract] [Full Text] [Related]
17. Real-world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post-marketing surveillance in Japan.
Takayama K; Kojima A; Honda C; Nakayama M; Kanemata S; Endo T; Muro K
Cancer Med; 2024 May; 13(9):e7170. PubMed ID: 38693813
[TBL] [Abstract] [Full Text] [Related]
18. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.
Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
[TBL] [Abstract] [Full Text] [Related]
19. E2F transcription factors promote tumorigenicity in pancreatic ductal adenocarcinoma.
Bertonnier-Brouty L; Andersson J; Kaprio T; Hagström J; Bsharat S; Asplund O; Hatem G; Haglund C; Seppänen H; Prasad RB; Artner I
Cancer Med; 2024 May; 13(9):e7187. PubMed ID: 38686617
[TBL] [Abstract] [Full Text] [Related]
20. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
[TBL] [Abstract] [Full Text] [Related]
[Next]